

ATHEROGENIC TRIAD IN OVERWEIGHT AND OBESE ADULTS IN BENIN-CITY, SOUTH-SOUTH NIGERIA

Abstract

Context: Atherogenic triad is a constellation of lipid abnormalities characterized by elevated small, dense low density lipoprotein particles, decreased high density lipoprotein particles and hypertriglyceridaemia.

Aim: This study determined the prevalence of atherogenic triad among the overweight and obese adults in Benin-City, South-South, Nigeria.

Setting and design: Study was conducted among overweight and obese adults in Benin City. It is a cross-sectional study.

Materials and methods: This study was conducted among 138 overweight and obese adults in Benin- City, Nigeria between July and September, 2016. Concentration of small, dense LDL-cholesterol was determined using precipitation method involving sodium-heparin and manganese II chloride as described by Hirano *et al.* Subjects were categorized into three groups (ideal weight, overweight and obese) based on their body mass index.

Results: The mean small dense LDL-cholesterol levels in the three groups were 0.79 ± 0.16 , 0.96 ± 0.15 and 1.33 ± 0.26 mmol/l respectively which were statistically different, triglyceride levels were 1.41 ± 0.73 , 1.33 ± 0.61 and 1.31 ± 0.73 mmol/L in the ideal weight, overweight and obese categories respectively while plasma HDL-cholesterol were 0.85 ± 0.20 , 1.05 ± 0.34 and 0.94 ± 0.30 mmol/L in the ideal weight, overweight and obese groups respectively. Elevated LDL-cholesterol was seen in more than 80% of the normal weight and the obese subjects and; 57.8% of the overweight subjects. Two (3.6%) obese subjects had

24 elevated sdLDL-C with LDL-C within the reference interval. Reduced HDL-C was found
25 more in the normal weight and obese subjects while atherogenic triad was detected in 7
26 (15.2%) of the obese.

27 **Conclusion:** The prevalence of atherogenic triad among the obese adult was 15.2%. The
28 prevalence of the atherogenic triad components were higher among the obese individuals than
29 the overweight. There is an urgent need for introduction of therapeutic lifestyle modification
30 among overweight and obese individuals in our population.

31 **Key words:** Atherogenic triad, overweight, obesity, small dense LDL-cholesterol, lipids.

32 **Key message:** Prevalence of atherogenic triad is high among the obese Nigerians. They are at
33 risk of cardiovascular diseases.

34 **Introduction**

35 Atherogenic triad, otherwise known as dyslipidaemic triad or lipid triad comprises of
36 elevated blood concentration of small, dense low density lipoprotein (sdLDL) particles,
37 decreased high density lipoprotein particles and increased triglyceride.¹ These lipid
38 abnormalities are typical features of obesity, metabolic syndrome, insulin resistance and type-
39 2 diabetes mellitus.² The involvement of lipid triad in the aetiopathogenesis of cardiovascular
40 diseases (CVD) has been well documented.³ CVD are the major cause of morbidity and
41 mortality worldwide with approximately 17.5 million deaths in 2005, among them, 7.6
42 million deaths from coronary heart disease and 5.7 million deaths from stroke. This figure has
43 been projected to rise to 20 million deaths in 2015.⁴

44 Low density lipoproteins are primary plasma lipid carriers in humans comprising of two
45 distinct subfractions: large buoyant LDL and small dense LDL particles⁵ that vary in their
46 size, density, physicochemical composition, metabolic behavior and atherogenicity. SdLDL
47 are lipoprotein fraction with density ranging from 1.019 to 1.063 g/ml. sdLDL particle has

recently emerged as an important risk factor for myocardial infarction and cardiovascular diseases.^{2,6} Generally, LDL particles are classified into four subclasses. These include: large (LDL I), intermediate (LDL II), small (LDL III) and very small (LDL IV) LDL subfractions. The LDLIII and LDLIV constitute the small dense LDL particle commonly referred to as phenotype pattern B with peak diameter of ≤ 25.5 nm. Increased atherogenicity of sdLDL is based on their specific biochemical and biophysical properties. Its small size favors their penetration into the arterial wall where they serve as a source of cholesterol and lipid storage.⁷ The association between lipids and coronary heart disease (CHD) has been well documented.⁵

Koba *et al.*, reported that small dense LDL are more atherogenic than large buoyant (lbLDL), they readily penetrate the arterial wall, higher affinity for the intimal proteoglycans, prolonged plasma half-life than buoyant LDL, low affinity for LDL receptor, low resistance to oxidative stress than buoyant LDL and they are easily engulfed by macrophages.⁸ SdLDL-C is elevated in patients with family history of premature coronary heart disease (CHD), hyperapobetalipoproteinaemia, familial combined hyperlipidaemia, familial dyslipidaemic hypertension, subclinical hypothyroidism and metabolic syndrome.⁹ From genome-wide association studies, proprotein convertase subtilisin kexin type-7 (PCSK7) gene has been found to be associated with sdLDL-C and other lipid factors.¹⁰

Highly atherogenic sdLDL-C are generated from VLDLI particles by the action of lipoprotein lipase, cholesterylester transport protein (CETP) and hormone sensitive lipase.¹¹ Environmental factors, abdominal adiposity, oral contraceptive use, diabetes mellitus and high carbohydrate diets are associated with elevated sdLDL-C.¹¹ Gazi *et al.*, reported the acceptance by National Cholesterol Education Program (NCEP)-Adult Treatment Panel III (ATP-III) of the sdLDL-cholesterol as an emerging CVD risk factor but no definite causal relationship was established properly due to close association between sdLDL-C,

73 triglycerides and other risk factor.¹² Small, dense LDL-C is now seen as a valuable screening
74 and preventive tool in the assessment of CVD most especially in patients with metabolic
75 syndrome¹³ and also featuring in some clinical guidelines for the management of
76 dyslipidaemia.¹⁴ Prevalence of dyslipidaemia has been reported to be high in all the six
77 geopolitical zones in Nigeria most especially reduced HDL-cholesterol and elevated LDL-
78 cholesterol.¹⁵ In apparently healthy and diabetic Nigerians, dyslipidaemia has been reported
79 as high as 60% and 89% respectively. Dyslipidaemia was also documented among obese
80 women in Southeastern Nigeria most especially elevated triglyceride, reduced HDL-
81 cholesterol and elevated LDL-cholesterol³⁴

82 This study assessed the pattern of dyslipidaemia as it relates to atherogenic triad among
83 overweight and obese adults in Benin City, Nigeria.

84 **Materials and methods**

85 A total of 138 subjects were recruited and categorized equally as ideal weight, overweight
86 and obese using the National Institute of Health criteria for body mass index classification
87 (NIH,2000). The study population consisted of male and female subjects between the ages of
88 18-65 years. Subjects were selected using systematic sampling method. They were recruited
89 from clients who came for routine investigations at the Centre for Disease Control and
90 Prevention (CDC Unit) of the Department of Community Health, UBTH, where apparently
91 healthy individuals are routinely screened for common diseases; the Metabolic Clinic of the
92 Department of Chemical Pathology in UBTH, where patients with metabolic diseases are
93 evaluated and managed. The controls (ideal weight individuals) with BMI of 18.5-25.0 kg/m²
94 were both male and female individuals between the ages of 18-65 years recruited from the
95 hospital workers. Subjects currently taking lipid-lowering agents, contraceptive and other
96 steroid were excluded. Pregnant and breastfeeding mothers were also excluded.

107 Ethical clearance was obtained from the Ethical Committee of the University of Benin
108 Teaching Hospital (ADM/E 22/A/VOL.VII/1078). Written consent was obtained from the
109 subjects.

100 Height was measured (to the nearest 0.1cm) using stadiometer (*RGZ-120*) with the subjects
101 standing erect against the wall on a horizontal floor without shoes. The head was positioned
102 in such a way that the external auditory meatus and the angle of the eye in horizontal plane.¹⁶

103 Body mass index (BMI) was calculated as weight divided by height metre square (kg/m^2).¹⁷
104 BMI of $>30 \text{ kg/m}^2$ was considered as obese and $25\text{-}29.9 \text{ kg/m}^2$ as overweight while among
105 the ideal weight controls; BMI was $18\text{-}24.9 \text{ kg/m}^2$.¹⁷ Waist circumference was measured
106 midway between the inferior margin of the last rib and the iliac crest in a horizontal plane
107 with the measuring tape not compressing the soft tissue and subject standing with feet 25-30
108 cm apart to ensure the weight is evenly distributed.¹⁸ Blood pressure (systolic and diastolic) in
109 mmHg was measured using sphygmomanometer and Litmann® stethoscope. The blood
110 pressure was taken using Accousson® sphygmomanometer with the subject in relaxed sitting
111 position.¹⁰⁹ The cuff was wrapped round the left mid upper arm; systolic blood pressure was
112 detected initially by palpation and later by the Korotkov sounds I and V to determine systolic
113 and diastolic pressures respectively.

114 Five milliliters (5 ml) of venous blood was collected under aseptic procedure from the
115 antecubital vein of all the subjects. Blood was dispensed into potassium ethylene diamine
116 tetraacetic acid (EDTA) specimen bottle for fasting plasma lipids profile (FPLP) and sdLDL-
117 cholesterol. Blood was centrifuged at 3000 revolutions per minute for 10 minutes, and plasma
118 separated and stored in -80°C freezer not later than 2 weeks before they were analysed.

119

120

Estimation of small dense LDL-cholesterol:

Small dense LDL-Cholesterol was determined by simple precipitation method. This was done by heparin-manganese precipitation according to the method of Hirano *et al* in 2003.¹⁹ Thirty (30) mmol/l of manganese II chloride, $MnCl_2$ was prepared by dissolving 1.485 g in 250 ml of distil water while 40 IU/ml sodium-heparin was prepared by adding 0.2 g of the salt into 500 ml of distil water (20,000 IU in 500 ml of distil water) since 100 IU sodium–heparin is equivalent to 1mg of the salt.¹⁹

Procedure for sdLDL-cholesterol estimation

1. The precipitation reagent (0.1 ml), containing 150 IU/ml heparin-sodium salt (*Elabscience*, LOT: AKOO17MAY13042) and 90 mmol/L Manganese II chloride tetrahydrate (*Loba Chemie*, LOT:L157011601) were added to each serum sample (0.1ml), mixed and incubated for 10 minutes at 37⁰C.

2. The samples were placed in an ice bath and allowed to stand for 15 minutes. This was followed by centrifugation 15,000 rpm for 15 minutes at 4⁰C using a cold centrifuge (*Rotina* 380R, Singapore).

3. An aliquot of the supernatant was taken for routine cholesterol analysis.

4. The cholesterol content was determined using enzymatic method (CHOD-PAP assay) for total cholesterol as described by Allain *et al*.

5. Small dense LDL-Cholesterol was calculated as: sdLDL-C= Measured cholesterol - HDL-C

Total cholesterol and triglyceride were determined using enzymatic methods²⁰ while HDL-cholesterol was determined using precipitation method as described by Burstein *et al*.²¹

Calculated LDL-cholesterol was estimated using Friedewald equation²³ (LDL-C mmol/L=

Total cholesterol- HDL-C – triglyceride/2.2) Non-HDL-cholesterol was estimated as the difference between total cholesterol and HDL-cholesterol. Control sera from Randox® (UK) (levels 1 and 3) were assayed for each run. Controls and standards were analysed 10 times to determine the mean, standard deviation and then coefficient of variation (CV=mean/standard deviation x 100) were calculated to determine the precision. The estimated CV for the various assays were: sdLDL-C (2.1%), total cholesterol (3%), and triglyceride (4%). These CVs were in agreement with values stated by the kit manufacturers. Their precisions are: sdLDL-C (97.7%), total cholesterol (97%) and triglyceride (96%). The reference intervals for various biochemical parameters were stated as plasma sdLDL-C(0.197 – 1.347 mmol/l), total cholesterol(2.38 -4.65 mmol/l),LDL – C (1.99 – 3.36 mmol/l), HDL – C (0.75 – 1.55 mmol/l), Triglyceride (0.22 – 0.87 mmol/l).

Data analysis

Data was analysed using the Statistical Package for Social Science (SPSS) version 20 (IBM Corp., Amonk, NY; released 2011). Data were tested for normality using Kolmogorov-Smirnov test and were found to be normally distributed. Results were expressed as mean ± standard deviation; student t-test and analysis of variance (ANOVA) were used for comparison of means between two groups and multiple groups respectively. Statistical significance was set at $p < 0.05$.

Results

One hundred and thirty-eight subjects made up of 88 females and 50 males were recruited in this study. They include 46 ideal weight, 46 overweight and 46 obese. Their mean ages of 55.57 ± 10.48 , 48.91 ± 8.33 and 45.11 ± 7.61 years respectively. Thirty-eight (82.6%) of the ideal weight subjects were females, 22 (47.8%) of the overweight subjects were males while 30 (65.2%) of the obese were females. Their means ages were 55.57 ± 10.48 , 48.91 ± 8.33

and 45.11 ± 7.61 years respectively. Thirty-eight (82.6%) of the normal weight subject were females, 22 (47.8%) of the overweight subjects were males while 30 (65.2%) of the obese were females. There was no statistical differences in their age distribution ($p=0.000$). Their anthropometric, clinical and biochemical parameters were measured and documented in the table I.

Anthropometric and clinical parameters.

The mean weight, height, BMI, waist circumference, hip circumference and waist hip ratio are shown in Table I. Using one-way ANOVA across the 3 groups, there was a significant difference ($p=0.000$) in the anthropometric parameters except the height ($p=0.054$) of the participants. More so, there was a significant difference ($p=0.000$) in systolic blood pressure, respiratory and pulse rates but no difference was found in diastolic blood pressure ($p=0.064$).

Biochemical profile of the subjects.

The average serum total cholesterol levels across the groups were 5.68 ± 0.99 , 5.36 ± 1.25 and 6.28 ± 1.05 mmol/L respectively ($F=2.9$; $p=0.000$). Serum triglyceride levels across the groups were not statistically different ($p=0.354$). There was reduced HDL-cholesterol among the normal weight subjects. There was no statistical difference between LDL-cholesterol levels between the normal weight and obese subject ($p=0.520$). Dyslipidaemia was observed across the three groups, most especially elevated LDL-cholesterol, elevated triglyceride, occurring in more than 70% of all the subjects. Elevated total cholesterol was seen in 95.7% of the obese subjects.

Highest mean values for serum total cholesterol, LDL-cholesterol and small dense LDL-cholesterol were recorded among the obese participants. Moreso, highest level of HDL-cholesterol was found among the overweight category while mean triglyceride level was the highest among the normal weight participants. The average sdLDL-cholesterol levels were

found to be 0.79 ± 0.16 , 0.96 ± 0.15 and 1.33 ± 0.26 mmol/l among the normal weight, overweight and obese participants respectively with a significant difference existing between the three groups ($F=7.3$, $p=0.000$). There was no significant difference in the serum levels of triglycerides among the groups ($F=1.1$; $p=0.354$). There was a significant difference in the means of all the biochemical parameters except serum triglyceride ($p=0.354$). There was no significant difference between LDL-C levels in normal weight and obese subjects ($p=0.520$). However, a statistically significant difference was found in sdLDL-C between normal weight and obese subjects ($p=0.000$). Dyslipidaemia was observed across the three groups; most especially elevated LDL-cholesterol elevated triglyceride occurring in more than 70% of all the subjects while elevated total cholesterol was seen in 95.7% of the obese subjects. Elevated sdLDL-C was seen in 10(12.7%) and 20(43.5%) of the overweight and obese subjects respectively, while atherogenic triad (a constellation of elevated triglyceride, reduced HDL-C and elevated sdLDL-cholesterol) was observed in 7(15.2%) of the obese subjects. There was no statistical difference between hypertriglyceridaemia across the three groups ($p=0.713$) unlike other abnormalities which were statistically significant ($p<0.05$). Moreso, 2 (3.6%) of the obese subjects had elevated sdLDL-C with LDL-C within the reference interval.

Table 1: Anthropometric and Clinical characteristics of the study subjects

Variables	Ideal Weight	Overweight	Obese		
	mean $\pm$ SD	mean $\pm$ SD	mean $\pm$ SD	F-value	p-value
Weight (Kg)	63.3 $\pm$ 9.48	75.54 $\pm$ 7.78	88.93 $\pm$ 10.65	7.6	0.000
Height (m)	1.68 $\pm$ 1.06	1.65 $\pm$ 0.08	1.61 $\pm$ 0.07	1.6	0.054
BMI (Kg/m ²)	22.19 $\pm$ 1.61	27.82 $\pm$ 1.16	34.28 $\pm$ 3.21	26.5	0.000
HC (cm)	86.99 $\pm$ 10.20	98.87 $\pm$ 7.94	98.56 $\pm$ 15.42	4.6	0.000
WC (cm)	90.48 $\pm$ 8.18	105.13 $\pm$ 7.39	117.0 $\pm$ 19.72	14.2	0.000
Age (years)	55.57 $\pm$ 10.48	48.91 $\pm$ 8.33	45.11 $\pm$ 7.61	46.3	0.000

Meal frequency	2.56±0.65	2.52±0.66	2.48±0.75	1.14	0.310
SBP (mmHg)	110±9.35	137.26±19.58	132.87±18.48	4.8	0.000
DBP (mmHg)	83.26±9.74	82.0±11.50	87.87±10.07	1.6	0.004
PR (bpm)	74.±12.0	74.13±11.81	75.96±11.93	1.7	0.040
RR (cpm)	13.35±1.34	16.17±10.33	14.3±1.40	123.4	0.000

210 BMI: Body mass index; WC: Waist circumference; HC: Hip – circumference; SBP: Systolic

211 blood pressure; DBP: Diastolic blood pressure; PR: Pulse rate; RR: Respiratory rate.

212 **Table 2:** Biochemical profile of study subjects.

	Ideal Weight	Overweight	Obese		
Variables	mean ±SD	mean±SD	mean±SD	F-value	p-value
TC (mmol/L)	5.68±0.99	5.36±1.25	6.28±1.05	2.9	0.000
TG (mmol/L)	1.41±0.73	1.33±0.61	1.31±0.73	1.1	0.354
HDL-C (mmol/L)	0.85±0.20	1.05±0.34	0.94±0.30	3.2	0.000
LDL-C (mmol/L)	4.61±1.09	3.70±1.09	4.75±1.04	2.8	0.000
sdLDL-C (mmol/L)	0.79±0.16	0.96±0.15	1.33±0.26	7.3	0.000

213 TC: Total cholesterol; TG: Triglyceride; HDL-C: High density lipoprotein-cholesterol; LDL-

214 C: Low density lipoprotein-cholesterol, sdLDL-C: small dense low density lipoprotein-

215 cholesterol.

216 **Table 3:** Frequencies of elevated biochemical parameters and lipid atherogenic triad in

217 normal weight, overweight and obese subjects.

Abnormalities	Ideal weight	Overweight	Obese		
	(n=46)	(n=46)	(n=46)	χ^2	p-value
Elevated TC	40 (87%)	32 (69.6%)	44 (95.7%)	10.12	0.006
Elevated TG	35 (76.1%)	35 (76.1%)	33 (71.7%)	0.676	0.713
Elevated LDL-C	39 (84.8%)	27 (58.7%)	41 (89.1%)	20.52	0.000
Elevated sdLDL-C	0 (0%)	10 (21.7%)	20 (43.5%)	46.78	0.000
Reduced HDL-C	18 (39.1%)	7 (15.2%)	18 (39.1%)	12.31	0.000

Atherogenic triad	0 (0%)	0 (0%)	7 (15.2%)	-	-
-------------------	--------	--------	-----------	---	---




Figure 1: Prevalence of components of atherogenic triad in overweight and obese subjects.

DISCUSSION

Atherogenic triad is characterized by elevated sdLDL cholesterol, increased triglyceride and reduced HDL-cholesterol. This has been reported to be of higher clinical significance than LDL-cholesterol as atherogenic triad is commonly found in patients with coronary artery disease, diabetes mellitus, obesity and metabolic syndrome.²³ Overweight or pre-obesity is defined as having more body fat than is optimally healthy²⁴ while obesity is a medical condition in which excess body fat has accumulated to the extent of having a negative effect

230 on the health of the individual.²⁵ Obesity arises from the combination of excessive food
231 intake, lack of physical activity and genetic susceptibility.²⁶

232 Atherogenic triad has been report as a feature of obesity and predisposes the obese to
233 cardiovascular diseases.²⁷ Alteration in lipoprotein metabolism leads to the elevation of lipid
234 particles rich in triglycerides remnants such as chylomicrons, very low density lipoprotein
235 (VLDL) and intermediate density lipoprotein (IDL). Like LDL, these remnant particles
236 readily penetrate the intima of arterial wall to cause atherosclerosis.²⁸

237 Presence of elevated triglyceride contributes immensely to the formation⁶ of sdLDL particles
238 from VLDL 1. HDL-C protects the arterial vessels from atherosclerosis as it promotes
239 reverse-cholesterol transport from cells in the vessel wall to the liver for elimination.²⁹

240 This study showed that the prevalence of atherogenic triad in the obese subjects as 15.7 %.
241 This prevalence is a bit reduced from the prevalence (24.08%) reported among Germans
242 population.²⁹ Dietary habits among the Germans could account for higher prevalence of
243 atherogenic triad seen in their population.²⁹

244 However, a lower prevalence of atherogenic triad was reported among the Spanish working
245 population.³⁰ Elevated sdLDL-Cholesterol has been reported as one of the additional
246 cardiovascular risk factor in most population.

247 This study observed an elevated sdLDL-C among the overweight (21.7%) and obese (43.5%)
248 subjects. The only study pointing to elevated sdLDL-Cholesterol among diabetics in Nigeria
249 was reported by Inaku *et al*; where the percentage sdLDL (%) among the diabetic patients
250 and control group were 45 ± 17.79 and $32 \pm 15.93\%$ respectively.³¹ Our study is also in
251 agreement with elevated sdLDL-C reported in adult Thai population. This implies that obese
252 and diabetic Nigerians are at risk of cardiovascular diseases.

Elevated triglyceride observed in more than seventy percent of overweight and obese in this study further support the previous studies that reported prevalence of hypertriglyceridaemia as 34.1% among women in South-Eastern Region, Nigeria.³² However, Iloh *et al* reported the prevalence of hypertriglyceridaemia as 4.7% among obese adult Nigerians.³³

The reduced HDL-C observed in this study also corroborates the findings reported by Oguejiofor *et al* who reported high prevalence of dyslipidaemia across the six geopolitical zones in Nigeria, most especially reduced HDL-cholesterol and elevated LDL-cholesterol among apparently healthy Nigerians.¹⁵ Our study is also in agreement with reduced HDL-C levels reported by Ilo *et al* among the adult population in Nigeria.³⁴

Abnormalities in blood lipids have been well reported among the overweight and obese individuals. Elevated LDL-cholesterol, triglyceride and low HDL-cholesterol are risk factors for the development of cardiovascular diseases. In this study; dyslipidaemia was observed across the three groups most especially elevated LDL-cholesterol which cut across the three groups. It was also observed that there is no significant difference between LDL-C levels in normal weight and obese subjects but a statistically significant difference seen in the sdLDL-C levels in both groups. These abnormalities may be a pointer to increased prevalence of metabolic syndrome and dyslipidaemia among normal weight, overweight and obese subjects in the larger population.

LIMITATION:

Reference interval for sdLDL-C used in the interpretation of the results is from Caucasian population as local reference interval for sdLDL-C is not available yet

CONCLUSION:

Atherogenic triad is 15.7% in the obese subjects while the prevalence of the components of atherogenic triad were high in the study population, most especially in the obese. These

findings necessitate institutionalizing preventive measures such as therapeutic lifestyle modification among the overweight and obese individuals to prevent cardiovascular diseases.

References

1. Girard-Mauduit S. The lipid triad or how to reduce residual cardiovascular risk. *Ann Endocrinol (Paris)*. 2010;71(2):89-94.
2. Musunuru K. Atherogenic dyslipidaemia: Cardiovascular risk and dietary intervention. *Lipids* 2010;45(10):907-914.
3. Manjunath CN, Rawal JR, Irani PM, Madhu K. Atherogenic dyslipidaemia. *Indian J Endocrinol Metab*. 2013;17(6):969-976.
4. Khan MS. Small Dense LDL: New Marker for Cardiovascular Risk Assessment and its Therapeutic Inflection. *Biochem Anal Biochem*. 2012; 1:e118. doi: 10.4172/2161-1009.1000e118.
5. Taylan E, Tuncel SB. Distribution of LDL subgroups in patients with hyperlipidaemia. *Turk J Med Sci* 2016;46:374-380.
6. Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small dense low density lipoprotein as biomarker for atherosclerotic diseases. *Oxidative Medicine and Cellular Longevity* 2017;12(7) 30-42.
7. Kulanuwat S, Tungtrongchitr R, Billington D, Davis IG. Prevalence of plasma small dense LDL is increased in obesity in a Thai population. *Lipids Health Disease* 2015;14:30-38.
8. Kazushito K, Kokoro T, Naoki S. LDL particle size and reactive oxygen metabolite in dyslipidemic patient. *Int.J.Prev. Med* 2013;(12):160-168.

- 300 9. Ayyobi AF, Mcgladdery SH, Austin MA, Arno G, Brunzell JD. Small, Dense LDL and
301 Elevated Apolipoprotein B are the common characteristics for the three Major Lipid
302 Phenotypes of Familial combined Hyperlipidemia. *Arterioscler Thromb Vasc Biol*
303 2003;1:1289-94.
- 304 10. Hoogeveen RC, Gaublatz JW, Sun W, Dodge RC, Crosby JR. Small dense LDL-
305 cholesterol concentration predicts risk for coronary heart disease: The ARIC Study.
306 *Arteriosclerosis, Thrombosis and Vascular Biology* 2014;34(5):1069-1077.
- 307 11. Verges B. Pathophysiology of diabetes dyslipidaemia: Where are we? *Diabetologia*
308 2015;58(5):886-99.
- 309 12. Gazi IF, Tsiminihodimos V, Tselepis AD, Clinical importance of and therapeutic
310 modulation of small dense low density lipoprotein particle. *Exp Opin Biol Ther*
311 2007;7(1):53-72.
- 312 13. Khalil RMAZ, Al-Azab DAM, Akl OA. Is small dense LDL a valuable screening tool
313 for cardiovascular disease in patients with metabolic syndrome. *Alexandria J Med.*
314 2017;53(4):299-305.
- 315 14. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber
316 AJ et al. American Association of Clinical Endocrinology and American College of
317 Endocrinologist Guidelines for management of dyslipidaemia and prevention of
318 atherosclerosis. AACE 2017 Guidelines. Available at
319 <https://www.aace.com/files/lipid-guidelines.pdf>. Accessed on 31st July, 2018.
- 320 15. Oguejiofor OC, Onwukwe CH, Odenigbo CU. Dyslipidaemia in Nigeria: Prevalence
321 and pattern. *Ann Afr Med.*2012;11(4):197-202
- 322 16. Carneiro Roriz AK, Santana Passos LC, Cunha De Oliveira C, Eickemberg M, De
323 Almeida Moreira P, Barbosa Ramos L. Anthropometric clinical indicators in the
324 assessment of visceral obesity: An update. *Nutr. Clin. Diet Hosp.* 2016;36(2):168–79.

- 325 17. Pasco JA, Holloway KL, Dobbins AG, Kotowicz MA, Williams LJ, Brennan SL. Body
326 mass index and measures of body fat for defining obesity and underweight: a cross-
327 sectional, population-based study. *BMC Obesity* 2014;1(9):1-7.
- 328 18. Chan DC, Watts GF, Barrett PHR, Burke V. Waist circumference, waist-to-hip ratio
329 and body mass index as predictors of adipose tissue compartments in men. *J Med*
330 2003;441-7.
- 331 19. Renjith R.S, Jayakumari N. A simple economical method for assay of atherogenic
332 small dense low density lipoprotein (sdLDL-C). *Indian J. Clin Biochem*
333 2011;26(4):385-388.
- 334 20. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of
335 total serum cholesterol. *Clin Chem.* 1974;20(4):470-475.
- 336 21. Burstein M, Scholnick HR, Morfin R. Rapid method for the isolation of lipoproteins
337 from human serum by precipitation with polyanions. *Scand J Clin Lab*
338 *Invest.* 1980;40: 583-595.
- 339 22. Friedewald.WT, Levy RI, Fredrickson DS. Estimation of the concentration of low
340 density lipoprotein-cholesterol in plasma. *Clin-Chem* 1972;18:499-502.
- 341 23. Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in
342 cardiovascular prevention? *J. Atheroscler Throm* 2005;12(5):237-9.
- 343 24. Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all- cause mortality with
344 overweight and obesity using standard body mass index categories. *JAMA*
345 2013;309(1):71-82.
- 346 25. Heymsfield SB, Wadden TA. Mechanism, pathophysiology, and management of
347 obesity. *New England Journal of Medicine* 2017;376:254-66.
- 348 26. Sudar EM, Zafi SS, Dobutovic BD, Obradovic MM, Soskic S, Jovanovic AA, et al.
349 Obesity as a risk factor for cardiovascular diseases: One of the biggest problems in

350 health care today.2013: 1(2) Cited 2015 July 5:Available from url:
 351 <http://www.iemest.eu/life-safety-and> security.

352 27. Lozan JV, Pallares V, Cea-Calvo L, Listerri JL, Fernandez-Perez C, Mart-Canalas JC,
 353 et al. Serum lipid profile and their relationship to cardiovascular diseases in elderly:
 354 The PREV-ICTUS study. *Curr Med Res Opin.* 2008;24: 659-670.

355 28. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, howard BV, Stein JH et al.
 356 Lipoprotein management in patient with cardiometabolic risk. *JACC*
 357 2008;51(15):1512-1524.

358 29. Bestehorn K, Smolka W, Pittrow D, Schulte H, Assman G. Atherogenic dyslipidaemia
 359 as evidenced by lipid triad: Prevalence and associated risk in statin-treated patients in
 360 ambulatory care. *Curr Med Res Opin.* 2010;26(12):2833-9.

361 30. Cabrera M, Sanchez-Chaparro MA, Valdiwelso P, Quevede-Aguado L, Catalina-
 362 Romero C, Fernandez-Labandera C et al. Prevalence of atherogenic dyslipidemia:
 363 Association with risk factors and cardiovascular risk in Spanish working population.
 364 *Atherosclerosis* 2014;235(2):562-569.

365 31. Inaku KO, Ogunkeye OO, Abbiyesuku FM, Chuhwak EK, Isichie CO, Imoh LC et al.
 366 Elevation of small, dense LDL-cholesterol: A possible antecedent of atherogenic
 367 lipoprotein phenotype in type 2 diabetes patients in Jos, Northcentral, Nigeria. *BMC*
 368 *Clin Pathol.* 2017;17:26-34.

369 32. Osuji CU, Nzerem BA, Meludu S, Dioka CE, Nwobodo E, Amilo GI. Prevalence of
 370 overweight/obesity and dyslipidemia among a group of women attending august
 371 meeting . *Nig Med J.* 2010;51(4):155-159.

372 33. Iloh G, Amadi AN, Nwankwo BO, Ugwu VC. Obesity in adult Nigerians: a study of
 373 its pattern and common primary comorbidities in a rural Mission general Hospital in
 374 Imo State, Southeastern Nigeria. *Nig J of Clin Pract.*2011;14(2):212-218.

375 34. Iloh G, Amadi AN, Njoku PU, Ofoedu JN, Awa-Madu J. The magnitude of abdominal
376 adiposity and atherogenic dyslipidemia among geriatric Nigerians with arterial
377 hypertension in a rural hospital in Southeastern Nigeria. Nig J Clin Pract.
378 2012;15(4):462-8.